 CARLSBAD, Calif., March 01, 2021 GLOBE NEWSWIRE -- Qualigen Therapeutics, Inc. NASDAQ: QLGN, a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announced today it has entered into a Material Evaluation and Option Agreement with the University College London UCL to advance development of and potentially expand toward future commercial uses of Qualigens leading anticancer drug candidate AS1411-GNP, also known as ALAN Aptamer-Linked Anti-Nucleolin. 